PRECISION

Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis - The New England Journal of Medicine - 2016

Brief Summary:

Among patients with RA and osteoarthritis and elevated CV risk requiring daily NSAID therapy, celecoxib is noninferior to ibuprofen and naproxen with regard to a primary safety outcome of cardiovascular death, nonfatal MI, and nonfatal stroke after mean follow up of nearly 3 years. Primary outcome events were low (approximately 2-3%) and similar among the three NSAIDs. GI events were significantly lower with celecoxib versus either naproxen or ibuprofen. Renal events were significantly lower with celecoxib versus ibuprofen.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/27959716